InvestorsHub Logo
Followers 6
Posts 541
Boards Moderated 0
Alias Born 09/14/2013

Re: jadite post# 20678

Saturday, 11/01/2014 1:53:02 AM

Saturday, November 01, 2014 1:53:02 AM

Post# of 30352
Even the NWHN didn't want Intrinsa approved. It was rejected due to the lack of safety data. And sales in Europe were dismal.

As for LibiGel, here are a few quotes from a Seeking Alpha article "Reviving the Blockbuster Potential of LibiGel..."

'As a professional statistician I was well aware of the weak evidence from Phase II studies of LibiGel".

In layman's terms, for Phase III trails, women's sexual satisfaction increased similarly between LibiGel and placebo".

These drugs were rejected like any other drugs based on weak data.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SEEL News